期刊文献+

马来酸曲美布汀对结肠平滑肌细胞钙激活钾通道的影响 被引量:11

Effect of trimebutine on the calcium activated potassium channel of colonic smooth muscle cells
下载PDF
导出
摘要 目的研究马来酸曲美布汀对豚鼠结肠平滑肌细胞膜钙激活钾通道的影响。方法酶解法急性分离单个豚鼠结肠平滑肌细胞,利用膜片钳技术在全细胞模式下记录钙激活钾电流[IK(ca)],用含有IK(ca)特异激动剂NS1619的生理盐水灌流细胞,使结肠平滑肌细胞处于超极化状态,检测给马来酸曲美布汀浓度分别为1.19μmol/L、5.95μmol/L、11.91μmol/L后的结肠平滑肌细胞膜IK(ca)。结果浓度为1.19μmol/L、5.95μmol/L、11.91μmol/L的马来酸曲美布汀可抑制豚鼠单个结肠平滑肌细胞膜IK(ca)(P均<0.01),当阶跃刺激为+80 mv时,其分别为超极化状态组的(65.87±4.80)%、(48.02±2.39)%、(18.88±2.29)%(P均<0.01)。结论马来酸曲美布汀能抑制豚鼠结肠平滑肌细胞钙激活钾通道的开放,使细胞兴奋性升高,且呈浓度依赖性,这可能是马来酸曲美布汀治疗肠易激综合征便秘症状的机制之一。 Objective To study the effect of trimebutine on the calcium activated potassium channel of colonic smooth muscle cells (SMCs). Methods Smooth muscle cells were isolated freshly from the colon strips of guinea pig by enzymolysis, the calcium activated potassium currents [ IK(ca) ] were recorded by patch clamp technique at whole cell model. The SMCs were perfused with pbysiologicalsaline (PSS) which contained NSl619-the calcium activated potassium channel's selective activator, causing the SMCs to be at the state of hyperpolarized. IK(ca) was detected when trimebutiue at different concentrations ( 1. 19, 5.95, 11.91 μ mol/L). Results Trimebutine at three concentrations ( 1.19, 5.95, 11.91 μmol/L) could inhibit the IK(ca) of single colonic SMCs ( all P 〈0.01 ). When stepped electrical stimulation parameter was 80 my, IK(ca) were (65.87±4.80)% , (48.02 ±2.39)% and (18.88±2.29)% compared with hyperpolarized state group (P 〈 0.01 ). Conclusion The results suggest that trimebutine can block the calcium activated potassium channel concentration-dependently and increase colonic SMCs' excitability. This may be one of the mechanisms of trimebutine in treatment of constipation symptom of IBS.
出处 《胃肠病学和肝病学杂志》 CAS 2011年第10期920-923,共4页 Chinese Journal of Gastroenterology and Hepatology
关键词 马来酸曲美布汀 钙激活钾通道 结肠平滑肌细胞 Trimebutine Calcium activated potassium channel Colonic smooth muscle cells
  • 相关文献

参考文献10

二级参考文献34

  • 1何东生,路逵阳,沈士刚,申耀宗.维生素K_3对Oddi′s括约肌作用的实验研究[J].徐州医学院学报,1994,14(1):53-54. 被引量:1
  • 2陈新谦 金有豫.新编药物学(第14版)[M].北京:人民卫生出版社,1998.48.
  • 3[1]Jaliwala J,Imperiale TF,Kroenke K.Pharmacologic treatment of the irritable bowel syndrome:A systematic review of randomized controlled trials[J].Ann Intern Med,2000,133(2)∶136-147.
  • 4[2]Thompson WG,Greed F,Drossman DA,et al.Functional bowel disease and functional abdominal pain[J].Gastroenterol Int,1992,15(6)∶75-91.
  • 5[3]Camilleri M,Northcatt AR,Kong S,et al.Efficacy and Safety of alosctron in woman with irritable bowel Syndrome:a randomised placebo-controlled[J].Lancet,2000,355(9209)∶1035-1040.
  • 6Williama CL,Villar RG, Peterson JM, et al. Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome.Gastroenterology, 1988,94 : 611-621.
  • 7Nagasaki M, kobayashi T, Tamaki H. Effects of trimebutine on cytosolic Ca^2 + and force transitions in intestinal smooth muscle. Eur J Pharmacol, 1991,195:317-321.
  • 8Nagasaki M, Komari S, Tamaki H, et al. Effect of trimebutine on K^+ current in rabbit ileal smooth muscle cells. Eur J Pharmacol,1993,235 : 197-203.
  • 9Nagasaki M, Komari S, Ohashi H, et al. Effect of trimebutine on voltage-activated calcium current in rabbit ileal smooth muscle cells.Br J Pharmacol, 1993,110:399-403.
  • 10Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J lnt Med Res,1997, 25:225-246.

共引文献168

同被引文献93

引证文献11

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部